Rep. Katie Porter (D-Calif.)--minus her "Whiteboard of Justice"--speaks at the U.S. Capitol on December 19, 2019. (Photo: Alex Wong/Getty Images)
May 18, 2021
U.S. lawmakers on Tuesday took the CEO of the maker of the world's bestselling drug to task for high product prices, with Rep. Katie Porter using her famed "Whiteboard of Justice" to demonstrate what she called "the Big Pharma fairy tale" that pharmaceutical research and development costs justify perpetual price hikes.
"The Big Pharma fairy tale is one of groundbreaking R&D that justifies astronomical prices. But the pharma reality is that you spend most of your company's money making money for yourself and your shareholders."
--Rep. Katie Porter
Members of the House Oversight Committee grilled AbbVie CEO Richard Gonzalez--whose total compensation topped $24 million last year (pdf)--about the reasons for increasing the price of its top-selling drug Humira to $77,000 for a year's supply.
Humira (adalimumab) is an immunosuppressant used to treat a wide range of inflammatory conditions including arthritis, Crohn's disease, psoriasis, and ulcerative colitis. Last year, Humira sales neared $20 billion, making it by far the world's bestselling pharmaceutical drug.
In January, Fortune reported AbbVie would raise the price of Humira by 7.4%. Why the increase? Drugmakers often claim higher prices are needed to fund research and development. AbbVie spent a total of $2.45 billion on R&D from 2013 to 2018.
Porter (D-Calif.) pointed out that the company spends nearly double that--$4.7 billion--annually on advertising.
\u201cBig Pharma says they need to charge astronomical prices to pay for research and development. Yet, the amount they spend on manipulating the market to enrich shareholders completely eclipses what's spent on R&D. Today, I confronted a CEO about the industry's lies, with visuals \u2935\ufe0f\u201d— Rep. Katie Porter (@Rep. Katie Porter) 1621363238
When Porter asked Gonzalez how much the company compensates its executives, the CEO said, "About $60 million a year."
"Try $334 [million] on for size," Porter shot back.
Noting that AbbVie spent around $50 billion on cumulative stock buybacks and dividends from 2013 to 2018, Porter then told Gonzalez: "You're spending all this money to make sure you make money rather than spending money to invest in [and] develop drugs and help patients with affordable, lifesaving drugs."
"You lie to patients when you charge them twice as much for an unimproved drug, and then you lie to policymakers when you tell us that R&D justifies those price increases," Porter asserted.
"The Big Pharma fairy tale is one of groundbreaking R&D that justifies astronomical prices," she said. "But the pharma reality is that you spend most of your company's money making money for yourself and your shareholders."
"The fact [is] that you're not honest about that with patients and policymakers--that you're feeding us lies that we must pay astronomical prices to get 'innovative' treatments," added Porter. "The American people, the patients, deserve so much better."
Why Your Ongoing Support Is Essential
Donald Trump’s attacks on democracy, justice, and a free press are escalating — putting everything we stand for at risk. We believe a better world is possible, but we can’t get there without your support. Common Dreams stands apart. We answer only to you — our readers, activists, and changemakers — not to billionaires or corporations. Our independence allows us to cover the vital stories that others won’t, spotlighting movements for peace, equality, and human rights. Right now, our work faces unprecedented challenges. Misinformation is spreading, journalists are under attack, and financial pressures are mounting. As a reader-supported, nonprofit newsroom, your support is crucial to keep this journalism alive. Whatever you can give — $10, $25, or $100 — helps us stay strong and responsive when the world needs us most. Together, we’ll continue to build the independent, courageous journalism our movement relies on. Thank you for being part of this community. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
U.S. lawmakers on Tuesday took the CEO of the maker of the world's bestselling drug to task for high product prices, with Rep. Katie Porter using her famed "Whiteboard of Justice" to demonstrate what she called "the Big Pharma fairy tale" that pharmaceutical research and development costs justify perpetual price hikes.
"The Big Pharma fairy tale is one of groundbreaking R&D that justifies astronomical prices. But the pharma reality is that you spend most of your company's money making money for yourself and your shareholders."
--Rep. Katie Porter
Members of the House Oversight Committee grilled AbbVie CEO Richard Gonzalez--whose total compensation topped $24 million last year (pdf)--about the reasons for increasing the price of its top-selling drug Humira to $77,000 for a year's supply.
Humira (adalimumab) is an immunosuppressant used to treat a wide range of inflammatory conditions including arthritis, Crohn's disease, psoriasis, and ulcerative colitis. Last year, Humira sales neared $20 billion, making it by far the world's bestselling pharmaceutical drug.
In January, Fortune reported AbbVie would raise the price of Humira by 7.4%. Why the increase? Drugmakers often claim higher prices are needed to fund research and development. AbbVie spent a total of $2.45 billion on R&D from 2013 to 2018.
Porter (D-Calif.) pointed out that the company spends nearly double that--$4.7 billion--annually on advertising.
\u201cBig Pharma says they need to charge astronomical prices to pay for research and development. Yet, the amount they spend on manipulating the market to enrich shareholders completely eclipses what's spent on R&D. Today, I confronted a CEO about the industry's lies, with visuals \u2935\ufe0f\u201d— Rep. Katie Porter (@Rep. Katie Porter) 1621363238
When Porter asked Gonzalez how much the company compensates its executives, the CEO said, "About $60 million a year."
"Try $334 [million] on for size," Porter shot back.
Noting that AbbVie spent around $50 billion on cumulative stock buybacks and dividends from 2013 to 2018, Porter then told Gonzalez: "You're spending all this money to make sure you make money rather than spending money to invest in [and] develop drugs and help patients with affordable, lifesaving drugs."
"You lie to patients when you charge them twice as much for an unimproved drug, and then you lie to policymakers when you tell us that R&D justifies those price increases," Porter asserted.
"The Big Pharma fairy tale is one of groundbreaking R&D that justifies astronomical prices," she said. "But the pharma reality is that you spend most of your company's money making money for yourself and your shareholders."
"The fact [is] that you're not honest about that with patients and policymakers--that you're feeding us lies that we must pay astronomical prices to get 'innovative' treatments," added Porter. "The American people, the patients, deserve so much better."
From Your Site Articles
U.S. lawmakers on Tuesday took the CEO of the maker of the world's bestselling drug to task for high product prices, with Rep. Katie Porter using her famed "Whiteboard of Justice" to demonstrate what she called "the Big Pharma fairy tale" that pharmaceutical research and development costs justify perpetual price hikes.
"The Big Pharma fairy tale is one of groundbreaking R&D that justifies astronomical prices. But the pharma reality is that you spend most of your company's money making money for yourself and your shareholders."
--Rep. Katie Porter
Members of the House Oversight Committee grilled AbbVie CEO Richard Gonzalez--whose total compensation topped $24 million last year (pdf)--about the reasons for increasing the price of its top-selling drug Humira to $77,000 for a year's supply.
Humira (adalimumab) is an immunosuppressant used to treat a wide range of inflammatory conditions including arthritis, Crohn's disease, psoriasis, and ulcerative colitis. Last year, Humira sales neared $20 billion, making it by far the world's bestselling pharmaceutical drug.
In January, Fortune reported AbbVie would raise the price of Humira by 7.4%. Why the increase? Drugmakers often claim higher prices are needed to fund research and development. AbbVie spent a total of $2.45 billion on R&D from 2013 to 2018.
Porter (D-Calif.) pointed out that the company spends nearly double that--$4.7 billion--annually on advertising.
\u201cBig Pharma says they need to charge astronomical prices to pay for research and development. Yet, the amount they spend on manipulating the market to enrich shareholders completely eclipses what's spent on R&D. Today, I confronted a CEO about the industry's lies, with visuals \u2935\ufe0f\u201d— Rep. Katie Porter (@Rep. Katie Porter) 1621363238
When Porter asked Gonzalez how much the company compensates its executives, the CEO said, "About $60 million a year."
"Try $334 [million] on for size," Porter shot back.
Noting that AbbVie spent around $50 billion on cumulative stock buybacks and dividends from 2013 to 2018, Porter then told Gonzalez: "You're spending all this money to make sure you make money rather than spending money to invest in [and] develop drugs and help patients with affordable, lifesaving drugs."
"You lie to patients when you charge them twice as much for an unimproved drug, and then you lie to policymakers when you tell us that R&D justifies those price increases," Porter asserted.
"The Big Pharma fairy tale is one of groundbreaking R&D that justifies astronomical prices," she said. "But the pharma reality is that you spend most of your company's money making money for yourself and your shareholders."
"The fact [is] that you're not honest about that with patients and policymakers--that you're feeding us lies that we must pay astronomical prices to get 'innovative' treatments," added Porter. "The American people, the patients, deserve so much better."
From Your Site Articles
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.